Shengjin Dou

528 total citations
36 papers, 347 citations indexed

About

Shengjin Dou is a scholar working on Otorhinolaryngology, Surgery and Oncology. According to data from OpenAlex, Shengjin Dou has authored 36 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Otorhinolaryngology, 24 papers in Surgery and 21 papers in Oncology. Recurrent topics in Shengjin Dou's work include Head and Neck Cancer Studies (27 papers), Salivary Gland Tumors Diagnosis and Treatment (16 papers) and Ear and Head Tumors (8 papers). Shengjin Dou is often cited by papers focused on Head and Neck Cancer Studies (27 papers), Salivary Gland Tumors Diagnosis and Treatment (16 papers) and Ear and Head Tumors (8 papers). Shengjin Dou collaborates with scholars based in China, United States and Russia. Shengjin Dou's co-authors include Guopei Zhu, Minjun Dong, Lai‐ping Zhong, Tingting Xu, Jiang Li, Sicheng Wu, Wen Jiang, Rongrong Li, Wu‐tong Ju and Lulu Ye and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Shengjin Dou

30 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shengjin Dou China	10	208	184	138	83	54	36	347
LP Kowalski Brazil	10	100 0.5×	95 0.5×	102 0.7×	48 0.6×	78 1.4×	15	305
Tatsumi Nagahashi Japan	11	128 0.6×	165 0.9×	197 1.4×	75 0.9×	58 1.1×	29	327
Anna Sophie Hoffmann Germany	8	111 0.5×	254 1.4×	113 0.8×	24 0.3×	35 0.6×	18	300
H Iro Germany	8	161 0.8×	157 0.9×	141 1.0×	60 0.7×	36 0.7×	28	316
Mioko Matsuo Japan	11	248 1.2×	163 0.9×	138 1.0×	86 1.0×	62 1.1×	69	394
N. Gopalakrishna Iyer Singapore	6	110 0.5×	167 0.9×	107 0.8×	47 0.6×	109 2.0×	7	355
Linda Weeks United States	5	220 1.1×	91 0.5×	227 1.6×	49 0.6×	39 0.7×	5	322
Shenhong Qu China	10	101 0.5×	81 0.4×	42 0.3×	48 0.6×	76 1.4×	58	290
Chris McConkey United Kingdom	6	82 0.4×	116 0.6×	254 1.8×	153 1.8×	89 1.6×	11	463
Floyd Christopher Holsinger United States	7	132 0.6×	226 1.2×	183 1.3×	111 1.3×	38 0.7×	14	315

Countries citing papers authored by Shengjin Dou

Since Specialization

Citations

This map shows the geographic impact of Shengjin Dou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjin Dou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjin Dou more than expected).

Fields of papers citing papers by Shengjin Dou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengjin Dou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjin Dou. The network helps show where Shengjin Dou may publish in the future.

Co-authorship network of co-authors of Shengjin Dou

This figure shows the co-authorship network connecting the top 25 collaborators of Shengjin Dou. A scholar is included among the top collaborators of Shengjin Dou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengjin Dou. Shengjin Dou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Wen, Ying Xiao, Haisheng Hu, et al.. (2025). Postoperative Intensity-Modulated radiotherapy with trigeminal nerve pathway delineation for head and neck adenoid cystic carcinoma. Radiotherapy and Oncology. 213. 111174–111174.

Dou, Shengjin, Xin Wang, Ying Xiao, et al.. (2025). Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis. Clinical and Translational Radiation Oncology. 53. 100945–100945.

Zhang, Zhen, Mengying Mao, Xiaoning Wang, et al.. (2025). Fusobacterium nucleatum ‐Derived Outer Membrane Vesicles Promote Immunotherapy Resistance via Changes in Tryptophan Metabolism in Tumour‐Associated Macrophages. Journal of Extracellular Vesicles. 14(4). e70070–e70070. 10 indexed citations

Jiang, Wen, et al.. (2025). Effectiveness of Early Oral Nutritional Supplementation in Preventing Weight Loss in Head and Neck Cancer Patients Undergoing Postoperative Radiotherapy or Chemoradiotherapy: A Prospective Randomized Controlled Trial. Journal of the American Nutrition Association. 44(6). 498–507.

Dou, Shengjin, Lin Zhang, Wen Jiang, et al.. (2024). Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study.. Journal of Clinical Oncology. 42(16_suppl). 6108–6108.

Jiang, Wen, Lan Chen, Rongrong Li, et al.. (2024). Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker. BMC Medicine. 22(1). 314–314. 5 indexed citations

Ju, Wu‐tong, Ying Liu, Jingjing Sun, et al.. (2023). Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study. International Journal of Surgery. 109(4). 879–886. 2 indexed citations

Dou, Shengjin, Lin Zhang, Rongrong Li, et al.. (2023). Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery. Clinical and Translational Radiation Oncology. 40. 100623–100623. 1 indexed citations

Ye, Lulu, Lin Zhang, Rongrong Li, et al.. (2023). Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study. Cancer Medicine. 12(8). 9144–9155. 5 indexed citations

10.

Jiang, Wen, Rongrong Li, Lin Zhang, et al.. (2023). Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial. Frontiers in Oncology. 13. 1072538–1072538. 1 indexed citations

11.

Ju, Wu‐tong, Ronghui Xia, Dongwang Zhu, et al.. (2022). A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nature Communications. 13(1). 78 indexed citations

12.

Li, Ruomei, et al.. (2020). A Phase II Trial of Radiotherapy Concurrent with Apatinib in Locally Advanced Bone and Soft Tissue Sarcoma of the Head and Neck: Preliminary Results. International Journal of Radiation Oncology*Biology*Physics. 108(3). S131–S132. 1 indexed citations

13.

Li, Rongrong, Wen Jiang, Shengjin Dou, et al.. (2020). A Phase 2 Trial of Chemoradiation Therapy Using Weekly Docetaxel for High-Risk Postoperative Oral Squamous Cell Carcinoma Patients. International Journal of Radiation Oncology*Biology*Physics. 107(3). 462–468. 6 indexed citations

14.

Ling, Yiqun, Guopei Zhu, Shengjin Dou, et al.. (2020). Effect of oral supplements on the nutritional status of nasopharyngeal carcinoma patients undergoing concurrent chemotherapy: A randomized controlled Phase II trial. Journal of Cancer Research and Therapeutics. 16(7). 1678–1678. 14 indexed citations

15.

Dou, Shengjin, Lenan Zhang, Ruomei Li, & Guopei Zhu. (2018). Phase 2 Study of Apatinib, A Novel VEGFR Inhibitor in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Preliminary Results. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1378–1379. 1 indexed citations

16.

Xiao, Feng, Shengjin Dou, Yida Li, et al.. (2018). Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes. Clinical & Translational Oncology. 21(6). 781–789. 4 indexed citations

17.

Dou, Shengjin, Wei Qian, Rongrong Li, Zhuoying Wang, & Guopei Zhu. (2016). Patterns of failure in head-and-neck cancer of unknown primary: a study of 92 patientshead-and-neck cancer of unknown primary. Zhonghua fangshe zhongliuxue zazhi. 26(1). 12–16. 1 indexed citations

18.

Li, Fei, et al.. (2015). An analysis of efficacy of intensity-modulated radiotherapy with concurrent chemotherapy for stage T1-2N1 nasopharyngeal carcinoma. Zhonghua fangshe zhongliuxue zazhi. 24(5). 529–532. 1 indexed citations

19.

Xu, Tingting, et al.. (2015). Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study. Oral Oncology. 51(9). 875–879. 50 indexed citations

20.

Qian, Wei, Guopei Zhu, Yulong Wang, et al.. (2014). Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation. Medical Oncology. 31(9). 178–178. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact